NGFR and cancer: Although a possible therapeutic strategy for highly invasive p75NTR-positive tumors, previous clinical attempts to inhibit the protease-rich environment of tumors using broad-spectrum MMP inhibitors have so far proven to be ineffective as anti-cancer agents, with phase II and III trials failing to show efficacy or survival benefit [76,77].